DBS Programming for Parkinson's Disease

Overseen By Joshua Wong, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: University of Florida

Disqualifiers: Atypical Parkinsonism, Personality, Mood, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 1 month

30 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

Deep brain stimulation (DBS) effectively alleviates motor symptoms in Parkinson's disease (PD). However, current programming is manual and time-consuming. This study will evaluate physiology-based programming using local field potentials (LFPs) to identify optimal stimulation parameters. Specifically, DBS contact selection based on beta power and a broad-band approach will be compared with conventional clinician-based programming.

Who Is on the Research Team?

Joshua Wong, MD

Principal Investigator

University of Florida

Are You a Good Fit for This Trial?

This trial is for individuals aged 21-89 with idiopathic Parkinson's Disease who meet specific clinical criteria. Participants must have a DBS implant (Percept device by Medtronic) to treat motor symptoms and be able to consent to the study. They should be available for initial programming sessions.

Inclusion Criteria

I am between 21 and 89 years old.

I can understand and agree to the study's details.

I have been diagnosed with Parkinson's disease according to the Movement Disorder Society.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo DBS programming using clinician-based and electrophysiology-based methods

1 month

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• DBS Programming

Trial Overview

The study tests new ways of setting up deep brain stimulation (DBS) using brain signals, comparing broad-band and beta power-based programming against standard clinician methods in Parkinson's patients, aiming to find more efficient settings.

How Is the Trial Designed?

Group I: Broad-band Experimental Treatment 1 Intervention

Group II: Clinician-based Active Control 1 Intervention

Group III: Maximum beta power-based Active Control 1 Intervention

Who Is Running the Clinical Trial?

University of Florida

Lead Sponsor

Trials

1,428

Recruited

987,000+